What's Happening?
Zealand Pharma experienced a significant drop in its stock value, losing around a third of its worth, after announcing phase 2 trial results for its obesity drug, petrelintide, developed in partnership with Roche. The trial, known as ZUPREME-1, involved
493 patients and showed that petrelintide achieved an average weight reduction of 10.7% over 42 weeks, compared to a 1.7% reduction with a placebo. Despite these results, the drug's performance was overshadowed by Eli Lilly's competing drug, eloralintide, which reported a 20% weight loss in a similar trial. Roche, however, remains optimistic about petrelintide's potential, citing its favorable tolerability profile and the absence of significant gastrointestinal side effects, which are common with other weight-loss drugs. The trial also revealed that female participants lost more weight than male participants.
Why It's Important?
The trial results are crucial as they highlight the competitive nature of the obesity drug market, where efficacy and tolerability are key factors for success. Zealand Pharma's stock decline reflects investor concerns about the drug's market potential compared to more effective alternatives. For Roche, the results are still promising, as they plan to explore petrelintide's use in combination therapies, potentially enhancing its market appeal. The outcome of this trial could influence future investment and development strategies in the obesity treatment sector, impacting stakeholders including pharmaceutical companies, healthcare providers, and patients seeking effective weight management solutions.
What's Next?
Roche and Zealand Pharma are awaiting results from the ZUPREME-2 trial, which focuses on patients with obesity and type 2 diabetes, expected in late 2026. Additionally, they plan to initiate a combination trial of petrelintide with another drug, CT-388, by the end of the year. These upcoming trials will be critical in determining petrelintide's future in the market and its potential role in combination therapies. The companies' strategies and the drug's performance in these trials will be closely watched by investors and competitors.
